ACC.24: The KARDIA-2 Study

ACC.24 — We are joined onsite by investigator, Dr Akshay Desai (Brigham and Women's Hospital, US) to discuss the findings from the KARDIA-2 randomized clinical trial (NCT05103332).

KARDIA-2 is a double-blind, placebo-controlled multicenter study aiming to evaluate the effects of zilbesiran, an RNA interference agent, on the systolic and diastolic blood pressure of hypertensive patients not adequately controlled by a standard-of-care antihypertensive medication.

672 patients were enrolled in the study, who were randomized to recieve treatment with either indapamide 2.5mg daily, amlodopine 5mg daily or olmesartan 40mga daily. After a run-in period, these arms were then again randomized to recieve either zilbesiran 60mg SC or placebo, in addition to indapamide, amlodopine or olmesartan.

Findings showed that treatment with a single subcutaneous dose of zilbesiran 600mg was associated with clinically significant reductions in 24 hour mean ambulatory and office systolic blood pressure compared with placebo at 3 months, when added to a diuretic, calcium channel blocker or maximum-dose angiotensin receptor blocker. This difference was sustained to 6 months in the indapamide and amlodipine cohorts despite add-on hypertensive therapy.

Interview questions:
1. What is the importance of this study?
2. What is the mechanism of action of zilbesiran?
3. What is the patient population and study design?
4. What are your key findings?
5. What are the clinical implications of these findings?
6. Where are the knowledge gaps, and what are the next steps?

Recorded onsite at the ACC Conference in Atlanta, 2024.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.